Summary Meningiomas are common, mostly benign, tumours arising from leptomeningeal cells of the meninges, which frequently contain mutations in the neurofibromatosis type 2 (NF2) gene. In this study, we analysed a protein product of the neurofibromatosis type 1 (NF1) gene, neurofibromin, in human established leptomeningeal cells LTAg2B, in 17 sporadic meningiomas and in a meningioma from a patient affected by NF2. The expression level of neurofibromin was determined by immunoblotting and immunoprecipitation with anti-neurofibromin antibodies. The functional status of neurofibromin was analysed through its ability to stimulate the intrinsic GTPase activity of p21 ras. In the cytosolic extracts of four sporadic meningiomas and in the NF2-related meningioma, the expression level and the GTPase stimulatory activity of neurofibromin were drastically reduced compared with the level present in the human brain, human established leptomeningeal cells LTAg2B and the remaining 13 meningiomas. Our results suggest that neurofibromin is expressed in leptomeningeal cells LTAg2B and in most meningiomas, i.e. tumours derived from these cells. The reduced expression and GTPase stimulatory activity of neurofibromin was found in about 23% of meningiomas and in the single NF2-related meningioma analysed. These results suggest that decreased levels of neurofibromin in these tumours may contribute to their tumorigenesis.
Neurofibromatosis type 1 (NFl) and neurofibromatosis type 2 (NF2) are the two most clearly defined diseases among neurofibromatoses (Mulvihill et al, 1990) . The incidence and clinical expressions of NFl and NF2 are quite different. While NFl is one of the most common autosomal, dominantly inherited disorders in humans (incidence 1 in 4000 to 1 in 3000 live births), NF2 is a very rare condition (incidence 1 in 40 000). Characteristic abnormalities in NFl include multiple neurofibromas, skin pigmentations called cafe au lait spots, axillary freckling, Lisch nodules of the iris and many other clinical manifestations (Riccardi, 1992) . The hallmark of NF2 is bilateral vestibular schwannomas, i.e. Schwann-cell tumours that arise from the vestibular branch of the eighth cranial nerve (Martuza and Eldridge, 1988) .
The phylogenetically conserved genes that are targets for NFl and NF2 reside on different chromosomes (chromosome 17 and 22 respectively) and both have been cloned in their entirety (Marchuk et al, 1991; Bemards et al, 1992; Rouleau et al, 1993; Trofatter et al, 1993) . The NFl gene encodes a 2818 amino acid protein, designated neurofibromin. A 360 amino acid region of neurofibromin shows significant homology to the catalytic domain of the mammalian p21 ras-specific 120-kDa GTPase-activating protein (p120 GAP), yeast equivalents IRAI and IRA2 proteins and recently identified mammalian p21 ras-specific GAPs (Ballester et al, 1990; Maekawa et al, 1994; Weisbach et al, 1994; Baba et al, 1995) . This GAP-related domain (GRD) of neurofibromin, as well as the full-length neurofibromin, can negatively regulate p21 ras in vitro by stimulating its weak intrinsic GTPase activity (Xu et al, 1990; Golubic et al, 1992) .
Normal cellular growth in response to peptide growth factors is dependent on the presence of functional p21 ras molecules in the cell (Stacey et al, 1991; Lowy and Willumsen, 1993) . The biological activity of p21 ras is regulated by guanosine triphosphate (GTP) binding and hydrolysis to guanosine diphosphate (GDP) (Lowy and Willumsen, 1993) . The GTP-bound form of p21 ras is biologically active, while p21 ras-GDP is inactive. Nearly all activating point mutations found in ras genes in numerous types of human tumours (Boss, 1989) decrease intrinsic GTPase activity of p21 ras and render it insensitive to stimulation by GAPs (Trahey and McCormick, 1987; Lowy and Willumsen, 1993) . The transforming activity of mutant p21 ras is, therefore, considered as the consequence of p21 ras being constitutively activated in its GTPbound state. Thus, loss of function of GAPs to negatively regulate the activity of p21 ras might be important in the tumorigenesis process. Supporting this idea, mutations of the NFl gene and reduced neurofibromin expression and catalytic activity were described in NFl-associated tumours and sporadic tumours of various types (Li et al, 1992; von Deimling et al, 1995) . Decreased expression of p120 GAP or its shorter placental isoform has been demonstrated in benign and malignant human trophoblastic tumours (Stahle-Backdhal et al, 1995) .
Meningiomas are tumours derived from leptomeningeal cells, specifically the arachnoid cap cells surrounding the brain and spinal cord. These tumours account for up to 20% of all primary intracranial neoplasms and 25% of intraspinal tumours (Russel and Rubinstein, 1989) . Although meningiomas are usually benign, they often recur after seemingly complete surgical removal and occasionally progress to a fully malignant phenotype (Kujas, 1993) . Clinically and histologically, meningiomas are a diverse group of tumours classified into different histological subtypes 747 (Scheithauer, 1990) . Little, however, is known about the molecular mechanisms responsible for the development and histopathological heterogeneity of these tumours . The NF2 gene seems to be the major meningioma gene because of its frequent mutational inactivation in sporadic meningiomas (Lutchman and Rouleau, 1996) . The levels of the NF2 protein, termed schwannomin (Rouleau et al, 1993) or merlin (Trofatter et al, 1993) , are severely reduced in almost 60% of sporadic meningiomas, as demonstrated in our recent analysis (Lee et al, 1997) . Besides the NF2 gene, several candidate meningioma genes were identified (Murphy et al, 1993; Peyrard et al, 1994; Lekanne Deprez et al, 1995) .
The possibility that the NFl gene plays a role in meningioma development has not been explored experimentally. Such plausibility, however, is supported by at least two observations. Firstly, some pathological features of NFl and loss of control of cell growth are apparent in neural crest-derived tissues (Basu et al, 1992; DeClue et al, 1992) , and meninges are thought to be partly of mesenchymal and partly of neural crest origin (O'Rahilly and Mueller, 1986) . Secondly, the involvement of NFI gene-bearing chromosome 17 in meningioma development is suggested by some cytogenetic studies (Yamada et al, 1980; Maltby et al, 1988) .
Mutational analysis of the NFl gene is complicated by its large size, numerous exons and the presence of pseudogenes (Li et al, 1995) . At least 80% of the identified mutations potentially encode truncated proteins because of premature translation termination (Heim et al, 1994; von Deimling et al, 1995) . As such, the analysis of neurofibromin by specific antibodies could reveal the consequences of most NF l mutations either by the presence of truncated proteins or by reduced expression of the full-length neurofibromin. The biochemical analysis of GAP activity of tumourderived neurofibromin could be used to determine effects of mutations that might occur in the GRD of the protein. The analysis of protein has an additional advantage. In contrast to the ubiquitous expression of the NFl gene, neurofibromin is predominantly expressed in the adult brain (Daston et al, 1992; Golubic et al, 1992) . Therefore, neurofibromin derived from non-tumorous cells present in the tumour, such as lymphocytes, macrophages, endothelial cells, etc., would have only minor significance in the interpretation of the results.
In this study, we determined first the expression level of neurofibromin in established human leptomeningeal cells, LTAg2B, using immunoblotting experiments with two specific antibodies. Then, to test the hypothesis that the loss of function of neurofibromin is involved in meningioma development, we determined the expression levels and the GAP activity of neurofibromin upon p21 ras in one NF2-related meningioma and in 17 primary sporadic meningiomas.
PATIENTS AND METHODS Tissue samples and cell lines
Human brain and tumour tissue specimens were obtained form the operating room with the patient's consent and approval of the Institutional Review Board (Cleveland Clinic Foundation IRB no. 5400). The NF2 patient, a 25-year-old woman, participating in this study met the criteria agreed upon in a consensus conference at the National Institutes of Health (Mulvihill et al, 1990) . She presented with bilateral vestibular schwannomas and multiple intracranial meningiomas. Normal brain specimen was obtained from an epilepsy patient with no apparent structural lesion and who was undergoing temporal lobectomy. Diagnosis of meningiomas and their histopathological classification was determined by neuropathologists. The leptomeningeal cell line LTAg2B was established from a primary culture of human leptomeningeal cells transfected with an SV40 T antigen construct (Murphy et al, 1991) . The cells were grown in minimum essential medium with Earle's salts (Gibco BRL) supplemented with 10% fetal calf serum and antibiotic-antimycotic agents. Murine fibroblast cells NIH 3T3 were grown in Dulbecco's modified eagle medium (DMEM) (Gibco BRL) supplemented with 10% calf serum and 1% penicillin/streptomycin. Human astrocytoma (CRT) cells, isolated from a grade IV glioblastoma, were grown in DMEM with 10% fetal calf serum (Estes et al, 1990) . kDa Preparation of tissue extracts Immediately upon surgical excision tumour or normal human brain tissue was transported on ice to the laboratory in buffer A (50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT and a cocktail of protease inhibitors). Tumour tissue was homogenized using a Polytron PT 3000 (Brinkmann) in buffer A. The homogenate was centrifuged at 100 000 g for 60 min, and the supernatant containing the cytosolic, soluble proteins (S100 fraction) and pellet was saved. The pellet was briefly homogenized, washed twice with buffer A and resuspended in buffer A containing 1% Triton X-100. After a 30-min incubation on ice, the sample was centrifuged at 100 000 g for 60 min at 4°C. Supernatant (1% Triton fraction) was saved and stored in aliquots along with SI00 fraction in an -850C freezer. The protein concentration of the tumour samples was determined using BCA protein assay reagent from Pierce, according to the protocol specified by the manufacturer, with a bovine serum albumin (BSA) standard.
LTAg2B, NIH3T3 and CRT cells were grown to confluence, washed three times in ice-cold phosphate-buffered saline (PBS) and scraped off the plates in buffer A. Cell lysates were prepared by sonication (3 x 10 s, 35% output) in a sonic dismembrator (Fisher, Model 300). All subsequent steps were performed as described above for brain and meningioma tissue samples.
Immunoblotting of neurofibromin and p120 GAP Total proteins from prepared fractions of the tumour lysates and positive control tissue were separated using standard 7% sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (SDS/PAGE) on a Bio-Rad Protean 11 16-cm cell. As a positive control, Sl00 fraction of rabbit and human brain was used, as the Immunoprecipitation was performed by anti-NFl GRP(N) IgG (indicated by N above) and anti-NF1 (ClI) serum (indicated by C above) from 2 mg of protein of rabbit brain (RB). A total of 2 mg of protein from meningiomas, with tumour number indicated at the bottom of the figure, was immunoprecipitated with anti-NF1 (Cl) serum (top) or with anti-p120 GAP IgG (bottom). Neurofibromin and p120 GAP immunoprecipitates were first used to measure their GTPase stimulatory activity and then boiled in Laemmli buffer followed by SDS/PAGE. Immunoblotting was done using anti-NF1 (Cl) serum (top) and anti-p120 GAP (bottom) Stripping of the anti-neurofibromin antibodies from membranes was performed for 30 min at 50°C in stripping buffer (62.5 mm Tris-HCI pH 6.8, 2% SDS, 100 mm 2-mercaptoethanol). The membranes were then washed four times for 5 min in TBS, 0.05% Tween 20 and incubated for I h at room temperature in blocking buffer (1% BSA in 10 mm Tris-HCI, pH 7.5, 100 mm sodium chloride, 0.1I% Tween 20).
Mouse monoclonal anti-p120 GAP antibody was obtained from Zymed and used according to the provided instructions. The secondary anti-mouse-horseradish peroxidase conjugated antibody (Boehringer) was diluted 1:5000 in 5% milk blocking buffer and incubated with the blots for I h at room temperature. Subsequent steps were performed as described for anti-neurofibromin immunoblotting.
Mouse monoclonal antibody to actin (Boehringer) was diluted in the blocking buffer (final concentration 0.5 jig ml-') and incubated at 4°C ovemight. Washing and subsequent steps were done as described for neurofibromin and pl20 GAP immunoblotting.
Immunoprecipitation of neurofibromin and p120 GAP To immunoprecipitate neurofibromin from tumour and control extracts, sodium chloride was added to obtain a final concentration of 100 mm along with the corresponding antibody. Anti-neurofibromin anti-NFIGRP(N) IgG and anti-NFIGRP(D) IgG were used at 1 jg per sample. The most efficient immunoprecipitation of neurofibromin, however, was achieved with anti-NF1(C1) polyclonal serum specific for the epitope at the carboxy terminus (residues 2798-2814) of human neurofibromin. This anti-neurofibromin serum was raised in our laboratory and was successfully used in immunoblotting and immunoprecipitation experiments using soluble and particulate fraction extracts of several murine organs (Golubic et al, 1992) . In the present study, 10 gl of serum was used per immunoprecipitation reaction. Two negative controls were used in the immunoprecipitation experiments. The first was immunoprecipitation with 10 jl of non-immune rabbit serum. In the second case anti-neurofibromin antibodies were neutralized by preincubation with 10-fold (by weight) excess of specific peptide antigen in PBS for 2 h at room temperature. For p120 GAP immunoprecipitation, a commercial anti-human p120 GAP polyclonal antibody was used (Upstate Biotechnology). This antibody was raised against GAP fusion protein containing amino acids 171-448 of human GAP and was used at 10 jg per sample. The incubation with antibodies was done at 4°C ovemight. About 35 jl of protein A Sepharose slurry (50% in buffer A) was added, and the samples were rotated on the wheel for 40 min at 4°C. The beads with immunoprecipitated neurofibromin were washed twice in buffer A containing 0.2% Nonidet-P40 and 100 mm sodium chloride, twice in buffer A containing 100 mm sodium chloride and once in buffer A. The p120 GAP immunoprecipitates were washed twice in buffer A containing 0.1% Nonidet-P40 and 75 mm sodium chloride, twice in buffer A containing 75 mM sodium chloride and once in buffer A. To reduce the background, the beads were settled down by gravity, except for the last wash when Eppendorf minifuge was used. The beads were then boiled in I x Laemmli buffer for 2 min and proteins were separated on SDS/PAGE. Protein transfer and immunoblotting were performed as described above.
GTPase assay with meningioma protein extracts The p21 ras GTPase stimulatory activity of the S100 fraction of meningiomas was determined by p21 ras immunoprecipitation assay. Figure 5 Immunoprecipitation of neurofibromin (grey bars) and p120 GAP (black bars) from the soluble fraction of meningiomas followed by GTPase assay. Ras indicates p21 ras 'zero' time (see Figure 4 legend), while N-im, indicates immunoprecipitation with non-immune serum from human brain tissue (HB). The numbers indicate each meningioma sample used for immunoprecipitation (see Table 1 )
Briefly, purified bacterially synthesized c-Ha-Ras was incubated for 5 min at 30°C with 1 ,UM [oc-32P]GTP (3000 Ci mmol'l; DuPont NEN) in buffer containing 20 mlv Tris-HCl, pH 7.5, and 1 mM DTT. The nucleotides were resolved on a polyethyleneimine cellulose thin-layer chromatography plate with a 1 M potassium phosphate, pH 3.4, mobile phase. The separated nucleotides were visualized and their intensity was determined using phosphoimager analysis.
GTPase assay with immunoprecipitated neurofibromin and p120 GAP
The p21 ras GTPase stimulatory activity of immunoprecipitated neurofibromin or p120 GAP was determined by p21 ras immunoprecipitation assay (Golubic et al, 1992) . Briefly, protein A-Sepharose beads with immunoprecipitated neurofibromin or p120 GAP were incubated for 15 mi at 30°C in the reaction buffer containing p2u1 ras, as described above. After incubation, rat monoclonal antibody Y13-259 and protein A-Sepharose beads coated with rabbit antibody to rat IgG were added to the supernatant. All subsequent steps were as described above.
RESULTS

Neurofibromin expression in established human leptomeningeal cell line LTAg2B
The level of neurofibromin expression wasCfrst determined in established human leptomeningeal cells LTAg2B, from which meningiomas are thought to develop (Russel and Rubinstein, 1989) . We have shown earlier that neurofibromin is predominantly expressed and catalytically active in the soluble fraction of the rat brain (Golubic et al, 1992 Neurofibromin expression in meningiomasimmunoprecipitation followed by immunoblotting experiments
In addition to immunoblotting, the expression level of neurofibromin in meningiomas was determined by immunoprecipitation of neurofibromin from the soluble fraction of the tumours followed by immunoblotting with anti-neurofibromin antibodies. As the availability of human brain tissue was limited, for immunoprecipitation experiments a soluble fraction of rabbit brain was used as a positive control. Figure 3A shows the results obtained after immunoprecipitation of neurofibromin from 4 mg of soluble fraction of several meningiomas with anti-NFIGRP(N) IgG or anti-NFIGRP(D) IgG followed by immunoblotting with anti-NFIGRP(N) IgG.
Immunoblotting of immunoprecipitated neurofibromin from seven meningiomas revealed a strong 250-kDa-specific band in five tumours (nos. 9, 10, 11, 12 and 17) ( Figure 3A) . In contrast to immunoblotting, anti-NFlGRP(D) IgG was much more efficient in immunoprecipitation than anti-GRP(N) IgG. Little neurofibromin, however, was immunoprecipitated even with anti-NFlGRP(D) IgG from meningiomas no. 7 and no. 8, thus confirming the observation made by immunoblotting (see Figure 2A and B). Very little, if any, neurofibromin was immunoprecipitated from meningioma no. 1 (Figure 3B ), no. 2 ( Figure 3C ) and tumours no. 14 and no. 18
( Figure 3D ) with anti-neurofibromin anti-NFl(CI) serum specific for the carboxy terminus of the protein. In contrast to the reduced level of neurofibromin seen in meningiomas nos. 1, 2, 7, 8, 14 and 18 by immunoprecipitation, the intensity of immunoprecipitated p120 GAP was similar in all tumours analysed (see Figure 3B and D for tumours nos. 1, 7 and 18; for other tumours data are not shown). The only exception was meningioma no. 14, in which p120 GAP was significantly reduced ( Figure 3D ).
In addition to neurofibromin, in some meningiomas (see tumours no. 7 and no.11 in Figure 3A ; no. 13 and no. 18 in Figure   3D ) a faster migrating band of about 200 kDa was also immunoprecipitated with both antibodies. The relationship of that protein to neurofibromin, however, is unknown. The presence of this band did not correlate with the reduction of neurofibromin, as it is detected in meningiomas no. 11 and no. 13, which expressed normal levels of neurofibromin. No other specific band of smaller size was detected by immunoprecipitation in any meningioma.
GTPase-activating protein (GAP) activity of neurofibromin from meningioma lysates At present, stimulation of p21 ras GTPase activity is the only known function of neurofibromin (Xu et al, 1990; Golubic et al, 1992) , and it was therefore used as another measure of neurofibromin levels in meningiomas. The GAP activity of neurofibromin from the soluble fraction of meningiomas was determined by p21 ras GTPase assay. A detergent dodecyl maltoside potently inhibits GAP activity of neurofibromin but not that of p120 GAP (Bollag and McCormick, 1991) and was used at a concentration of 1.25 mM to determine the contribution of neurofibromin to the total GAP activity of meningioma lysates. The total GAP activity minus maltoside-insensitive activity is due to neurofibromin. The total and dodecyl maltosidesusceptible GAP activity of the soluble fraction of 18 meningiomas (tumours no. 1 through to no. 18) and rabbit brain as a positive control were determined ( Figure 4A and B) .
The GTPase stimulatory activity of tumours nos. 2, 5, 9, 11, 13, 15 and 18 contained maltoside-susceptible GAP activity similar to that seen in brain tissue ( Figure 4A and B) . In five meningiomas (nos. 1, 6, 7, 8 and 14) , GAP activity was only weakly susceptible to inhibition by maltoside ( Figure 4A and B) and therefore contained little GTPase-stimulatory activity upon p21 ras that could be attributed to neurofibromin.
Although results of this functional analysis of neurofibromin mostly correlated well with the results of the previous experiments (exceptions were tumours no. 2 and no. 18), their interpretation is complicated by recent identification of other p21 ras-specific GAP proteins in the brain tissue (Maekawa et al, 1994; Weisbach et al, 1994; Baba et al, 1995) . At present, it is not known whether these proteins are expressed in meningiomas and whether their GAP activity is susceptible to inhibition by maltoside.
GAP activity of immunoprecipitated neurofibromin
To eliminate the possibility that other p21 ras-specific GAP molecules (Maekawa et al, 1994; Weisbach et al, 1994; Baba et al, 1995) , besides neurofibromin and p120 GAP, contribute to the total and maltoside-sensitive GAP activity of meningioma lysates, neurofibromin and p120 GAP were immunoprecipitated from the soluble fraction of meningiomas, and the GAP activity of immunoprecipitated proteins was determined in p21 ras GTPase assay.
Neurofibromin was immunoprecipitated from 4 mg of the soluble fraction from 12 meningiomas with the anti-NFI(CI) polyclonal antibody specific for the epitope at the carboxy terminus of human neurofibromin. The GAP activity of immunoprecipitated neurofibromin was high in meningiomas that had previously shown good maltoside-susceptible GAP activity (tumours nos. 9-13 and 15-17). The average GAP activity of immunoprecipitated neurofibromin in these meningiomas was 83% (range 75-97%; standard deviation 7.5) of the activity detected in neurofibromin immunoprecipitated from the soluble fraction of human brain ( Figure 5 and Table 1 ). In contrast, GAP activity of immunoprecipitated neurofibromin from meningiomas nos. 1, 7, 8, 14 and 18 was substantially reduced ( Figure 5 and Table 1 ). Immunoprecipitated neurofibromin from meningiomas nos. 1, 8 and 14 had only 16%, 19% and 27% of GAP activity of neurofibromin from human brain tissue respectively (Table 1 ). The reduction of neurofibromin's GAP activity from tumours no. 7 and no. 18 was less severe (42% and 38% respectively). Results similar to those in Figure 5 and Table 1 were obtained when GAP activity of neurofibromin was determined after its immunoprecipitation from 2 mg of soluble protein from meningiomas (not shown).
Immunoprecipitation with anti-p120 GAP antibody was also performed as a control. In contrast to the substantial reduction of GAP activity of immunoprecipitated neurofibromin from meningiomas nos. 1, 7, 8, 14 and 18, the p120 GAP GTPase stimulatory activity was either unchanged or slightly reduced in these tumours compared with other meningiomas with good neurofibromin expression (see Figure 5 and Table 1 ). To better estimate the degree of neurofibromin reduction in these meningiomas, the ratio British Journal of Cancer (1997) 76(6) 
DISCUSSION
This study resulted in several novel observations concerning the role that neurofibromin might play in meningioma tumorigenesis. After extensive analysis using four different methods, we show for the first time that neurofibromin is expressed at high levels in leptomeningeal cells and in sporadic meningiomas, their tumour derivatives. Furthermore, reduced expression and consequently diminished GAP activity of neurofibromin were found in about 28% of the tumours analysed.
Neurofibromin expression in the adult nervous system was found by immunostaining of tissue sections limited to neurons, oligodendrocytes and non-myelinating Schwann cells (Daston et al, 1992) . This study provides evidence that neurofibromin is also highly expressed in the established human leptomeningeal cell line. Although LTAg2B cells might differ from native leptomeningeal cells, at least by morphology and expression of tissue markers, they are indistinguishable from arachnoid cells of leptomeninges (Murphy et al, 1991) . As determined by immunoblotting, these cells abundantly expressed full-length neurofibromin at levels 10-fold higher than murine NIH 3T3 fibroblast and human astrocytoma cell line CRT. In contrast, the expression level of p120 GAP was found to be similar among these cells. The high expression level of neurofibromin in the leptomeningeal cell line suggests that functions of neurofibromin in these cells could be physiologically important, as already shown for Schwann cells (Basu et al, 1992; DeClue et al, 1992; Takahashi et al, 1995) and neurons (Vogel et al, 1995) .
Based on results obtained by immunoprecipitation and immunoblotting experiments, we concluded that 11 out of 18 meningiomas expressed neurofibromin at levels similar or slightly reduced compared with human brain tissue. The results of the GTPase assay with the soluble fraction of meninigiomas and neurofibromin immunoprecipitated from these tumours were compatible with the neurofibromin expression data (Table 1) .
In five tumours (meningioma nos. 1, 6, 7, 8 and 14) , the expression levels of neurofibromin and neurofibromin's GAP activity were reduced in comparison to other meningiomas. Reduced expression of neurofibromin was also found in meningioma no. 2 by immunoblotting with amino and carboxy terminus-specific antibodies (Figure 2 ) and immunoprecipitation with the antibody recognizing an epitope at the carboxy terminus of the molecule ( Figure 3C ). In tumour no. 18, reduced neurofibromin was detected only by immunoprecipitation with antibody directed against the carboxy terminus of the protein ( Figure 3D and Table 1 ). Consequently, GAP activity of immunoprecipitated neurofibromin from tumour no. 18 was reduced (meningioma no. 2 was not analysed using this assay) ( Figure 5 and Table 1 ). Examination of the maltoside-susceptible GAP activity of these two meningiomas, however, suggested that neurofibromin is catalytically active at levels similar to other meningiomas with normal neurofibromin expression (Figure 4) . The discrepancy in tumour no. 18 could be explained by the presence of an altered epitope site at the carboxy terminus of neurofibromin that prevented efficient immunoprecipitation. The conflicting finding of the obvious reduction of neurofibromin expression and the presence of maltoside-susceptible activity in meningioma no. 2 can be explained by the presence of maltoside-susceptible GAP activity that is distinct from neurofibromin. It is not known, however, whether other p21 ras-specific GAPs are susceptible to inhibition by maltoside (Maekawa et al, 1994; Weisbach et al, 1994) .
In contrast to alterations found in neurofibromin, the expression levels and catalytic activity of the other p21 ras-specific GTPase stimulatory protein, p120 GAP, were similar in all meningiomas except in malignant tumour no. 14. In this tumour, both neurofibromin and p120 GAP were reduced. The reduction of GAP activity of neurofibromin, however, was more severe than that of p120 GAP (Table 1) .
No association between the age of meningioma detection and neurofibromin status was found. There was also no clear correlation between tumour location and reduced expression of neurofibromin. Reduced neurofibromin expression and its GAP activity were found in all histological types of sporadic tumours examined, except in a single fibroblastic meningioma. This occurred in meningiomas of meningotheliomatous (four out of nine, 44%), transitional (two out of five, 40%) and malignant (one out of three, 33%) histological types. The reduced neurofibromin expression and GAP function was therefore not associated with any particular histological type. Surprisingly, a meningioma derived from an NF2 patient had a severely reduced expression level and GAP activity of neurofibromin. As expected, the analysis of protein extracts from that tumour indicated an absence of schwannomin/merlin (not shown).
Recently we found that frequency of schwannomin/merlin reduction in meningotheliomatous meningiomas was significantly lower than in other histological tumour types (Lee et al, 1997) . This suggests that development of meningotheliomatous meningiomas is probably linked with alterations in other oncogenes or tumour-suppressor genes. Interestingly, three of four meningotheliomatous tumours with altered neurofibromin (nos. 6, 8 and 18) expressed normal levels of schwannomin/merlin (Lee et al, 1997) . One interesting possibility is that neurofibromin and schwannomin/merlin control similar or interacting biochemical intracellular pathways and that disruption of either one contributes to meningioma development.
Both neurofibromin and schwannomin/merlin might be involved in signalling through the p21 ras pathway. Recent study suggests that the tumour-suppressor activity of schwannomin/merlin could be mediated through its anti-p21 ras function (Tikoo et al, 1994) . Neurofibromin is considered to act as a negative regulator of p21 ras (Lowy and Willumsen, 1993) and as its effector (Moodie et al, 1995) . Reduced neurofibromin expression in meningiomas could lead to changes in both functions because five meningiomas with reduced catalytic activity of neurofibromin expressed little of the full-length protein. No meningioma with a normal neurofibromin expression level and impaired GAP activity was found, suggesting that GRD of neurofibromin in these tumours was functionally intact. Therefore, it is likely that the inactivating mutations described in GRD of neurofibromin in other tumour types (Li et al, 1992) are absent or are rare in meningiomas.
The lack of knowledge about p21 ras expression and alterations in meningiomas further obscures the role of neurofibromin in p21
Neurofibromin in meningiomas 755 ras signalling in meningiomas (Salgaller et al, 1990; Arvanitis et al, 1991) . More data indirectly suggest p21 ras importance. The strong inappropriate expression (compared with normal leptomeningeal cells) of polypeptide growth factors and their receptors on the same population of meningioma cells suggests the important possibility of autocrine or paracrine functions for these factors (Todo et al, 1996) . Because extracellular growth factors found in meningiomas act through protein tyrosine kinase receptors and activate p21 ras, the reduced expression of neurofibromin and the consequent decrease in both the negative regulation of p21 ras and/or its effector activity might be of importance in the tumorigenesis of meningiomas. If neurofibromin is the major regulator of p21 ras in leptomeningeal cells or meningiomas, as in the Schwann cells (Basu et al, 1992; DeClue et al, 1992) , then the diminished GTPase stimulatory activity of neurofibromin would result in an increase of the proportion of p21 ras bound to GTP. Neurofibromin, however, does not stimulate GTPase activity of oncogenically activated p21 ras (Trahey and McCormick, 1987) . It remains to be demonstrated whether oncogenic mutations in p21 ras occur in meningiomas and whether proliferation of meningiomas is dependent on the presence of the functional p21 ras.
